Apogee director granted 7,657 stock options

Apogee Therapeutics director Jennifer A. Fox received a new stock option grant.

Rhea-AI Filing Summary

Apogee Therapeutics director Jennifer A. Fox received a new stock option grant. She was awarded options to buy 7,657 shares of common stock at an exercise price of $85.0000 per share. The option vests on the one-year anniversary of the grant date and expires on June 9, 2036, reflecting a compensation-related award rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 7,657 shares

Grant/Award 1 txn

Insider Fox Jennifer A.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	7,657	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 7,657 contracts (Direct)

Footnotes (1)

1. F1. This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

Key Figures

Option grant size: 7,657 shares Exercise price: $85.0000 per share Expiration date: June 9, 2036 +1 more

4 metrics

Option grant size 7,657 shares Stock Option (Right to Buy) awarded to director

Exercise price $85.0000 per share Exercise price for the stock option grant

Expiration date June 9, 2036 Option expiration for granted stock options

Derivative holdings after grant 7,657 options Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), vest, exercise price, expiration date

4 terms

Stock Option (Right to Buy) financial

"This option represents the right to purchase 7,657 shares of the Issuer's common stock"

vest financial

"will vest on the one-year anniversary of the grant date"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"conversion_or_exercise_price: "85.0000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-09T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Apogee Therapeutics (APGE) director Jennifer A. Fox report on this Form 4?

Jennifer A. Fox reported receiving a stock option grant for 7,657 shares of Apogee Therapeutics common stock. The options are a compensation award, not an open-market trade, and give her the right to buy shares at a preset exercise price.

How many Apogee Therapeutics shares are covered by Jennifer A. Fox’s new options?

The new option grant covers 7,657 shares of Apogee Therapeutics common stock. Each option represents the right to purchase one share if exercised, giving her potential future ownership tied to the company’s stock performance and ongoing service.

What is the exercise price of Jennifer A. Fox’s Apogee Therapeutics stock options?

The options have an exercise price of $85.0000 per share. This means she can buy Apogee Therapeutics common stock at this fixed price if she chooses to exercise the options after they vest, regardless of the market price then.

When do Jennifer A. Fox’s Apogee Therapeutics stock options vest?

The options will vest on the one-year anniversary of the grant date, subject to her continued service with Apogee Therapeutics. Vesting means she must remain in her role for that year before she can exercise the right to purchase shares.

When do Jennifer A. Fox’s Apogee Therapeutics stock options expire?

The stock options expire on June 9, 2036. After this expiration date, any unexercised options become worthless, so she must exercise vested options before that deadline if she wishes to acquire the underlying shares.

Did Jennifer A. Fox buy or sell Apogee Therapeutics stock in the market?

This filing does not show any open-market buying or selling of Apogee Therapeutics stock. It reports only a grant of stock options as compensation, which provides potential future ownership rather than an immediate market transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 08:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fox Jennifer A.

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$85	06/09/2026		A		7,657		(1)	06/09/2036	Common Stock	7,657	$0.00	7,657	D

Explanation of Responses:

1. This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

	/s/ Matthew Batters, as attorney-in-fact for Jennifer Fox	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)